Clinical Trial Detail

NCT ID NCT03456076
Title A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Participants With ALK Positive Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

non-small cell lung carcinoma

Therapies

Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Vinorelbine

Alectinib

Age Groups: senior adult

Additional content available in CKB BOOST